ELAGOLIX: AN INVESTIGATIONAL TREATMENT FOR UTERINE FIBROIDS
Gonadotropin-releasing hormone, or GnRH, is a peptide that stimulates the secretion of the pituitary hormones that are responsible for sex steroid production and normal reproductive function.
Elagolix, in combination with add-back therapy, is an orally active, non-peptide GnRH antagonist, being investigated for the treatment of uterine fibroids. It is believed that elagolix may be able to alter the level of pituitary GnRH suppression thereby titrating circulating hormone levels and may provide patients relief from the painful symptoms associated with uterine fibroids.
Pursuant to the collaboration between Neurocrine Biosciences and AbbVie, AbbVie is investigating elagolix for uterine fibroids. In August 2019, AbbVie, in cooperation with Neurocrine Biosciences, announced the submission of a New Drug Application (NDA) submission to the FDA for elagolix for the management of heavy menstrual bleeding (HMB) associated with uterine fibroids in women. AbbVie is responsible for all development, marketing and commercialization costs of elagolix.